# A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Source: https://onco.cc/trials/nct07235293/  
OnCo record `nct07235293` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Atezolizumab, Fruquintinib in colorectal cancer, run by Kahr Bio Australia Pty Ltd, now recruiting.

## Summary

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. is a phase 2 interventional study registered as NCT07235293 by Kahr Bio Australia Pty Ltd, with 90 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09-30. Interventions recorded: DSP107 + Atezolizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07235293
- Phase: 2
- Setting: A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer
- Sponsor: Kahr Bio Australia Pty Ltd
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07235293: https://clinicaltrials.gov/study/NCT07235293

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07235293.json